Targeting the PKCiota/USP14/GPX4 pathway might be developed to be a targeted therapeutic strategy for ESCC, especially for patients with loss of miR-145-5p, PRKCI amplification, mutation of Lys to other amino acids in GPX4, or activation of USP14. This evidence concerns the gene PRKCI and esophageal squamous cell carcinoma.